

# Yingcheng Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2142545/publications.pdf>

Version: 2024-02-01

29  
papers

947  
citations

687363

13  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

965  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. <i>Cancer Discovery</i> , 2022, 12, 134-153.	9.4	286
2	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. <i>Cancer Cell</i> , 2022, 40, 70-87.e15.	16.8	120
3	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and TIGIT) in advanced melanoma. <i>Journal of Clinical Investigation</i> , 2022, 132, e151111.	5.1	85
4	Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2019, 10, 2451.	4.8	69
5	Spatial omics: Navigating to the golden era of cancer research. <i>Clinical and Translational Medicine</i> , 2022, 12, e696.	4.0	53
6	Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2022, 13, 1642.	12.8	40
7	The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. <i>International Journal of Cancer</i> , 2017, 141, 2562-2570.	5.1	35
8	A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. <i>Cell Reports</i> , 2019, 29, 3435-3447.e4.	6.4	33
9	EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 2779-2788.	1.4	27
10	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. <i>Oncotarget</i> , 2018, 9, 7942-7948.	1.8	27
11	Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints. <i>International Journal of Cancer</i> , 2019, 144, 1657-1663.	5.1	21
12	Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7696-7706.	2.6	17
13	HPV shapes tumor transcriptome by globally modifying the pool of RNA binding protein-binding motif. <i>Aging</i> , 2019, 11, 2430-2446.	3.1	14
14	Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. <i>Frontiers in Oncology</i> , 2022, 12, 822449.	2.8	12
15	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. <i>Biotarget</i> , 0, 1, 7-7.	0.5	11
16	C-terminal binding protein 2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis. <i>International Journal of Oncology</i> , 2018, 53, 167-176.	3.3	11
17	Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model. <i>International Journal of Cancer</i> , 2018, 143, 3038-3040.	5.1	11
18	Multi-omics analysis reveals the functional transcription and potential translation of enhancers. <i>International Journal of Cancer</i> , 2020, 147, 2210-2224.	5.1	11

#	ARTICLE	IF	CITATIONS
19	The endoribonuclease N4BP1 prevents psoriasis by controlling both keratinocytes proliferation and neutrophil infiltration. <i>Cell Death and Disease</i> , 2021, 12, 488.	6.3	11
20	Identification of prognostic risk factors for pancreatic cancer using bioinformatics analysis. <i>PeerJ</i> , 2020, 8, e9301.	2.0	9
21	A comprehensive competitive endogenous RNA network pinpoints key molecules in diabetic retinopathy. <i>Molecular Medicine Reports</i> , 2018, 19, 851-860.	2.4	8
22	The C-terminal low-complexity domain involved in liquid-liquid phase separation is required for BRD4 function in vivo. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 807-809.	3.3	8
23	Survival-Associated Alternative Splicing Events in Pan-renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1317.	2.8	8
24	The identification of gene signature and critical pathway associated with childhood-onset type 2 diabetes. <i>PeerJ</i> , 2019, 7, e6343.	2.0	4
25	Decoding the complexity of metastasis. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-5.	3.0	4
26	SPACE: a web server for linking chromatin accessibility with clinical phenotypes and the immune microenvironment in pan-cancer analysis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1294-1296.	10.5	3
27	The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0187902.	2.5	1
28	Wide-ranging analysis of survival-related alternative splicing events in invasive breast carcinoma. <i>Oncology Letters</i> , 2020, 20, 1866-1878.	1.8	1
29	Super-enhancers modulate interleukin-6 expression and function in cancers. <i>Translational Cancer Research</i> , 2020, 9, 5555-5565.	1.0	1